Skip to content
The Policy VaultThe Policy Vault

Ojemda (tovorafenib) — Medica

Pediatric low-grade glioma

Initial criteria

  • age ≥ 6 months
  • relapsed or refractory disease
  • tumor positive for ONE of the following: BRAF fusion OR BRAF rearrangement OR BRAF V600 mutation

Approval duration

1 year